<DOC>
	<DOC>NCT01824303</DOC>
	<brief_summary>The purposes of the study is to determine if LiRIS®, an investigational drug-delivery system, is safe and tolerable in women with Interstitial Cystitis (IC), and to evaluate any change in IC symptoms following LiRIS administration.</brief_summary>
	<brief_title>Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis</brief_title>
	<detailed_description>The study is conducted in 2 parts: a randomized, blinded part in which subjects are assigned randomly (by chance) to LiRIS 400 mg or LiRIS placebo; subjects who complete this part and are eligible to continue, may participate in the open-label part in which all subjects receive LiRIS 400 mg. In both parts of the study (blinded and open-label), LiRIS is inserted into the bladder during cystoscopy, remains in the bladder for 14 days, and is removed during cystoscopy. In addition to the 14 day period with the LiRIS/LiRIS Placebo, there is a screening period of up to 2 weeks and a follow up period of 4 weeks.</detailed_description>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis, Interstitial</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Inclusion Criteria Blinded study: Women age 18 and over Diagnosed with Interstitial Cystitis as defined by protocol Able to report IC symptoms of bladder pain, voiding habits, as required by protocol, and record in diary Able to comply with visit schedule and diary completion at home Openlabel Extension: Must have completed the blinded study prior to screening for the Openlabel extension Exclusion Criteria (Blinded and OpenLabel Extension): Pregnant or lactating women History or presence of any condition that would make it difficult to accurately evaluate bladder symptoms Bladder or urethral abnormality that would prevent safe insertion of investigational product Requiring medication not allowed per study protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>